Proactiveinvestors Australia Kazia Therapeutics Ltd https://www.proactiveinvestors.com.au Proactiveinvestors Australia Kazia Therapeutics Ltd RSS feed en Sat, 20 Jul 2019 05:27:40 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52% ]]> https://www.proactiveinvestors.com.au/companies/news/223644/kazia-therapeutics-substantial-holder-willoughby-capital-increases-interest-to-1752-223644.html Kazia Therapeutics Ltd (ASX:KZA) substantial holder Hishenk Pty Ltd has increased its interest in the company from 17.4% to 17.52% after purchasing 55,000 shares on-market.

This comes after the holder reiterated its confidence in the biotechnology company’s oncology drug develoomet last week by increasing its share to 17.4% from 13.8%.

Due to a restructure, the Kazia shares are now held by Willoughby Capital Pty Ltd ATF Willoughby Capital Trust, an associated entity of Hishenk due to common directors and shareholders.

 

Kazia is developing GDC-0084 brain penetrant PI3K inhibitor GDC-0084 and a third generation benzopyran drug, Cantrixil.

Licensed from Genentech in October 2016, GDC-0084 is a novel targeted therapy that inhibits the PI3K pathway, important in many forms of cancer and activated in 85-90% of GBM cases.

Glioblastoma multiforme is the most common and aggressive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in one-third of patients.

Furthermore, the median survival rate is 12-15 months from diagnosis, meaning there is demand in the market for superior treatments.

]]>
Wed, 10 Jul 2019 02:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223644/kazia-therapeutics-substantial-holder-willoughby-capital-increases-interest-to-1752-223644.html
<![CDATA[News - Kazia Therapeutics substantial shareholder lifts interest to 17.4% ]]> https://www.proactiveinvestors.com.au/companies/news/223348/kazia-therapeutics-substantial-shareholder-lifts-interest-to-174-223348.html Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) substantial shareholder Hishenk Pty Ltd has reiterated its confidence in the biotechnology company’s oncology drug development by increasing its interest to 17.4% from 13.8%.

The holding of the Sydney-based investor was boosted to 10.835 million shares on June 26 with another 1.844 million shares accumulated.

Since October 3 last year Hishenk and related entities have participated in a placement and purchased shares on-market, increasing the holding from around 6.685 million shares.

Today Kazia traded up almost 4% to A$0.40.

READ: Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research

Edison Investment Research has recently assigned an indicative valuation range of A$84–135 million or A$1.35–2.17 per share for the company.

This follows identification of a higher maximum tolerated dose (MTD) from a Phase IIa study of its brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor GDC-0084 in glioblastoma (GBM).

The result may lead to improved efficacy in the ongoing expansion cohort and planned Phase IIb study.

READ: Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment

GBM multiforme is the most common and aggressive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in one-third of patients.

Furthermore, the median survival rate is 12-15 months from diagnosis, meaning there is demand in the market for superior treatments.

Kazia is developing GDC-0084, a brain penetrant PI3K inhibitor licensed from Genentech, and a third-generation benzopyran drug, Cantrixil.

A new collaboration with the Alliance for Clinical Trials in Oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers.

Further data from the Cantrixil Phase I study in ovarian cancer expected in the second half of 2019.

]]>
Thu, 04 Jul 2019 18:13:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223348/kazia-therapeutics-substantial-shareholder-lifts-interest-to-174-223348.html
<![CDATA[News - Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research ]]> https://www.proactiveinvestors.com.au/companies/news/223001/kazia-therapeutics-has-two-novel-classes-of-anti-cancer-drugs-edison-investment-research-223001.html Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has identified a higher maximum tolerated dose (MTD) from a Phase IIa study of its brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor GDC-0084 in glioblastoma (GBM), which may lead to improved efficacy in the ongoing expansion cohort and planned Phase IIb study.

READ: Kazia Therapeutics' ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients

GBM multiforme is the most common and aggressive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in one-third of patients.

Furthermore, the median survival rate is 12-15 months from diagnosis, meaning there is demand in the market for superior treatments.

Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia.

Following is an extract from Edison’s pipeline update on Kazia:

Kazia Therapeutics is an Australian biotechnology company focused on oncology drug development, listed on both the ASX (KZA) and Nasdaq (KZIA).

It is developing GDC-0084, a brainpenetrant PI3K inhibitor licensed from Genentech, and a third-generation benzopyran drug, Cantrixil.

A new collaboration with the Alliance for Clinical Trials in Oncology (Alliance) means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers.

It also expects further preliminary efficacy data from its Cantrixil Phase I study in ovarian cancer in H219.

Higher MTD for GDC-0084 in target population

Kazia’s Phase I study showed that recently diagnosed GBM patients were able to tolerate a higher (and therefore potentially more efficacious) dose of its oral PI3K inhibitor GDC-0084 than Genentech had reported from its prior study in patients with late-stage disease. A 20-patient expansion cohort is expected to report top-line efficacy data in Q419.

GDC-0084 is targeting an unmet need in GBM

The GBM trials will test GDC-0084 in patients who have an unmethylated MGMT promotor. This subgroup (~61% of GBM patients) obtains little benefit from standard temozolomide chemotherapy. Kazia may seek to position the planned Phase IIb study in GBM as a pivotal study designed to support filing for approval for this patient population who have no effective treatments. If this strategy is accepted, Kazia could be in a position to file for approval in this indication in 2023.

New collaboration targeting brain metastases

Kazia’s collaboration with the Alliance will target brain metastases that have genetic alterations of the PI3K pathway. The Phase II study will target brain metastases from a wide range of solid tumour types, allowing Kazia to fully capitalise on the capacity of GDC-0084 to penetrate the brain. The trial is expected to be completed in 2021.

Cantrixil expansion cohort data in H219

Potential efficacy signals from the 12-patient expansion cohort of the Phase I study of Cantrixil in ovarian cancer are expected to read out in H219. We expect Kazia to seek a partner to support the further development of Cantrixil in this indication.

Valuation: Adjusted to A$84–135m in two scenarios

We adjust our indicative valuation range to A$84–135m or A$1.35–2.17/share (vs A$84–146m, A$1.36–2.34/share), due to revised timelines for post-Phase III approval or single-pivotal-study approval scenarios for GDC-0084. Kazia had A$5.4m cash at 31 December 2018 and will likely need to raise funds in H219. We estimate ~A$15–20m will be needed to fully fund the GDC-0084 Phase IIb study.

]]>
Fri, 28 Jun 2019 12:34:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223001/kazia-therapeutics-has-two-novel-classes-of-anti-cancer-drugs-edison-investment-research-223001.html
<![CDATA[News - Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment ]]> https://www.proactiveinvestors.com.au/companies/news/220551/kazia-therapeutics-to-collaborate-with-us-based-oncology-foundation-on-clinical-trials-for-metastatic-brain-cancer-treatment-220551.html Kazia Therapeutics Ltd (ASX:KZA) has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance) to launch a multi-centre phase-two study investigating the potential use of Kazia’s GDC-0084 drug in treating brain metastases.

The US-based cancer research network is sponsored by the National Cancer Institute and will also investigate several other targeted cancer therapies.

 

Kazia chief executive officer James Garner said the Alliance study was a ground-breaking research project that aims to investigate several experimental drugs in a single clinical study.

He said: “Patients will be allocated to treatment depending on their tumour’s individual genetic signature and patients with a mutation affecting the PI3K pathway will be eligible to receive GDC-0084.

“This kind of approach is very much the future of cancer treatment.”

READ: Kazia Therapeutics’ ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma

Alliance is to initiate the open-label phase-two study which will allocate to patients either abemaciclib (Eli Lilly), entrectinib (Genentech) or Kazia’s GDC-0084, based on the genetic profile of their tumour.

The trial is expected to recruit up to 150 patients across multiple US medical centres and Kazia will support it by providing the study drug and a financial grant.

Only patients with a genetic alteration in the PI3K pathway will receive GDC-0084, which is expected to comprise about one-third of total patients recruited.

Patients with other genetic mutations will receive either CDK inhibitor abemaciclib, approved by the Federal Drug Administration (FDA) for treatment of certain forms of breast cancer, or Trk/ALK inhibitor entrectinib which has not yet been approved by the FDA.

READ: Kazia Therapeutics’ studies evaluate therapeutic candidates in ovarian cancer and brain tumours

Harvard Medical School Assistant Professor of Medicine and principal investigator of the study Priscilla Brastianos said brain metastases represented an unmet clinical need.

She said: “We urgently need to find better treatment options for these patients.

“We hope this study will help us identify a new treatment paradigm.”

 

The study is expected to take about two years to complete and will be conducted under an “investigator IND” with the US FDA, where Alliance will assume primary regulatory responsibilities for the study.

Implementation of the study is conditional on approval from applicable institutional review boards and completion of contractual formalities, which have not yet been finalised.

Kazia anticipates patient recruitment will begin in the second half of this year.  

]]>
Sun, 19 May 2019 22:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220551/kazia-therapeutics-to-collaborate-with-us-based-oncology-foundation-on-clinical-trials-for-metastatic-brain-cancer-treatment-220551.html
<![CDATA[News - Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon ]]> https://www.proactiveinvestors.com.au/companies/news/219839/kazia-therapeutics-gains-new-substantial-holder-in-the-bank-of-new-york-mellon-219839.html Kazia Therapeautics Limited (ASX:KZA) has a new substantial holder in The Bank of New York Mellon Corporation (NYSE:BK) which recently staked a 27.09% interest.

The world’s largest custodian bank now holds a total of 16,840,686 securities in the Australian oncology-focused biotech company.

 

 

Kazia Therapeutics chief executive officer James Garner said the superior results from the ongoing study of GDC-0084 in newly-diagnosed glioblastoma patients was an important milestone for the company.

He added the current, second stage of the two-part study (which began in September) will transition into observing more patients, with higher doses of the drug.

READ: Kazia Therapeautics’ ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients

Garner continued: “One of the exciting things about our drug GDC-0084 is that its designed to cross the blood-brain barrier.

“We are focusing on newly-diagnosed patients in earlier stages of the disease and we think we can offer a much bigger benefit there.”

The company confirmed a higher maximum tolerated dose (MTD) of 60 milligrams in new safety data from its ongoing phase-IIa clinical study earlier this week.

]]>
Wed, 08 May 2019 14:56:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219839/kazia-therapeutics-gains-new-substantial-holder-in-the-bank-of-new-york-mellon-219839.html
<![CDATA[Media files - Kazia Therapeutics releases new safety data to assist in brain cancer treatments ]]> https://www.proactiveinvestors.com.au/companies/stocktube/13249/kazia-therapeutics-releases-new-safety-data-to-assist-in-brain-cancer-treatments-13249.html Tue, 07 May 2019 21:02:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/13249/kazia-therapeutics-releases-new-safety-data-to-assist-in-brain-cancer-treatments-13249.html <![CDATA[News - Kazia Therapeutics' ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients ]]> https://www.proactiveinvestors.com.au/companies/news/219706/kazia-therapeutics--ongoing-study-confirms-higher-drug-tolerability-in-newly-diagnosed-glioblastoma-patients-219706.html Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has confirmed a higher maximum tolerated dose (MTD) of 60 milligrams in new safety data from its ongoing phase-IIa clinical study of GDC-0084 in newly-diagnosed patients with glioblastoma (GBM).

Licensed from Genentech in October 2016, GDC-0084 is a novel targeted therapy that inhibits the PI3K pathway, important in many forms of cancer and activated in 85-90% of GBM cases.

Glioblastoma multiforme is the most common and aggressive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in one-third of patients.

Furthermore, the median survival rate is 12-15 months from diagnosis, meaning there is demand in the market for superior treatments.

 

Kazia chief executive officer James Garner said this was an important milestone and the company was encouraged by the results.

The MTD of 60 milligrams is substantially higher than the 45-milligram dose found during Genentech’s phase-I study in patients with recurrent disease.

Dose-limiting toxicities in this phase-IIa study included oral mucositis (mouth ulcers) and hyperglycemia (elevated blood sugar), both of which are expected effects of the PI3K inhibitor class of drugs.

READ: Kazia Therapeutics studies evaluate therapeutic candidates in ovarian cancer and brain tumours

Garner said: “Genentech’s original phase-one study examined GDC-0084 in very advanced patients, who are often less able to tolerate therapy.

“They reached an MTD of 45 milligrams which is expected to be within the therapeutic range.

“When we licensed the drug from Genentech, we recognised the opportunity to refocus around newly-diagnosed patients, who are often in generally better health.

“The fact that the drug appears better tolerated here than in the previous study validates our strategy for GC-0084 and bodes well for the clinical efficacy of the drug.”

 

Kazia’s phase-IIa study of GDC-0084 is designed in two parts, the first of which began dosing in September last year and is now complete.

This was a dose optimisation component designed to determine if newly-diagnosed patients could tolerate a higher dose of GDC-0084 than advanced recurrent patients.

The second part is the dose expansion cohort, designed to provide confirmatory efficacy signals, for which Kazia expects to report initial data in the fourth quarter of calendar year 2019.

Kazia will recruit a further 20 patients for the dose expansion cohort, on top of the eight already recruited in the dose optimisation component.

READ: Kazia Therapeutics progresses phase II clinical trial for brain cancer drug

Garner continued: “The total clinical experience with GDC-0084 is now approaching 70 patients.

“The side effects that we have seen to date have all been very typical for this type of drug: mouth ulcers, high blood sugar, etc.

“Critically, we have not seen any of the more serious side effects that have sometimes been observed with other drugs in the class, such as infections, liver toxicity, or gastrointestinal problems.

“This is very reassuring as we prepare to take the drug forward into the next phase of development.”

]]>
Mon, 06 May 2019 00:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219706/kazia-therapeutics--ongoing-study-confirms-higher-drug-tolerability-in-newly-diagnosed-glioblastoma-patients-219706.html
<![CDATA[News - Kazia Therapeutics studies evaluate therapeutic candidates in ovarian cancer and brain tumours ]]> https://www.proactiveinvestors.com.au/companies/news/219425/kazia-therapeutics-studies-evaluate-therapeutic-candidates-in-ovarian-cancer-and-brain-tumours-219425.html Kazia Therapeutics Ltd (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) (FRA:NV9M) is a mid-stage Australian biotechnology company specialising in oncology-focused pharmaceutical drug development. The multi-listed Sydney company is undertaking a number of clinical trials in humans in the United States and Australia under the guidance of the US Food and Drug Administration.

The junior Australian company appeared at this year’s American Association of Cancer Research annual meeting in Atlanta, Georgia, to present phase I data from a study of its Cantrixil treatment for ovarian cancer.

Kazia is focused on spreading word of its results in ovarian cancer with Cantrixil and glioblastoma multiforme (GBM) brain cancer therapy GDC-0084 to investors, being profiled in a number of closely-followed junior-stock media outlets in recent months.

Kazia is led by chief executive officer & executive director Dr James Garner, a life sciences executive and trained physician with strong experience in regional and global new medicine development from preclinical evaluation through to commercialisation staging. Garner has worked with Biogen and Takeda, led research and development strategy for Sanofi for the Asia-Pacific region and was previously a strategy consultant for Bain & Company.

What does Kazia Therapeutics own?

The key assets are Cantrixil, which is being studied as a treatment for ovarian cancer, and GDC-0084 which is being looked at as a potential therapy for a more severe type of brain cancer.

First-in-class development candidate Cantrixil (TRX-E-002-1) targets the full spectrum of cancer cells, including tumour-initiating cells which may cause cancer recurrence.

The study of the intra-peritoneal (IP)-delivered chemotherapy candidate in patients at US and Australian hospitals falls under Kazia’s investigational new drug application approved by the FDA in 2016.

Cantrixil has potential as a treatment for late-stage disease — stages III and IV — which currently have poor survival ratings.

Kazia is hopeful its therapeutic could become a front-line therapy for the killer disease as oncologists seek to extend patient survival times and reduce relapse rates among successfully-treated patients.

Ovarian cancer is a lucrative drug market for cancer therapeutics companies, with the US$500 million industry tipped to grow to US$1 billion within a five-year period.

Another cancer with often poor prognosis is brain cancer.

Brain tumours or malignant glioblastomas such as grade IV glioblastoma multiforme claim many lives, with treatments offering poor prognosis.

Kazia’s solution to glioblastoma multiforme is the targeted therapy GDC-0084 which modulates the phosphoinositide-3-kinase (PI3K) signalling pathway.

PI3K is disordered in more than 85% of GBMs, and in a number of other cancers, not just brain tumours.

GDC-0084 works by crossing the blood-brain barrier, an important aspect to affecting brain tissue.

Genentech previously showed GDC-0084 had acceptable tolerability in a patient group of people with advanced brain tumours, the majority with GBM.

GDC-0084 also reduced tumour size in some patients, as presented at the ASCO Annual Meeting in June 2016.

Clinical study of the therapeutic by Kazia started last year as it sought definitive proof-of-concept clinical data.

Inflection points

Clinical trial milestones and endpoints

Funding milestones, clinical trial phasing and pipeline progression

Significant transactions

Kazia CEO Dr James Garner pleased with ovarian cancer candidate

“We’ve had some really good feedback actually … one of the things that’s been exciting is that in addition to the safety data we’ve presented, there’s some pointers that our drug [Cantrixil] is working,” Kazia CEO and executive director Dr James Garner told Proactive Investors last month.

“We saw more than half of the [ovarian cancer] patients (in) stable disease, that suggest that the drug is slowly or stopping the progression of their cancer.”

 

]]>
Wed, 01 May 2019 18:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219425/kazia-therapeutics-studies-evaluate-therapeutic-candidates-in-ovarian-cancer-and-brain-tumours-219425.html
<![CDATA[Media files - Kazia Therapeutics to present positive ovarian cancer drug data at AACR annual meeting ]]> https://www.proactiveinvestors.com.au/companies/stocktube/12814/kazia-therapeutics-to-present-positive-ovarian-cancer-drug-data-at-aacr-annual-meeting-12814.html Mon, 01 Apr 2019 22:45:00 +1100 https://www.proactiveinvestors.com.au/companies/stocktube/12814/kazia-therapeutics-to-present-positive-ovarian-cancer-drug-data-at-aacr-annual-meeting-12814.html <![CDATA[News - Kazia Therapeutics will outline anti-cancer drug development strategy at CEO Sessions ]]> https://www.proactiveinvestors.com.au/companies/news/214129/kazia-therapeutics-will-outline-anti-cancer-drug-development-strategy-at-ceo-sessions-214129.html Kazia Therapeutics Ltd (ASX:KZA) is developing anti-cancer drugs with its pipeline including two clinical-stage drug development candidates and the company’s progress will be outlined at this month’s Proactive CEO Sessions.

Chief executive officer James Garner will present to investors at the Sydney CEO Session on Monday, February 18 and at the Melbourne session on Tuesday, February 19.

Its lead candidate is GDC-0084, which entered a phase II clinical trial in March 2018, and Kazia expects  initial data early this year followed by other data read-outs.


GDC-0084 is being developed for glioblastoma multiforme, the most common and most aggressive form of primary brain cancer.

Chemotherapy treatment temozolomide is only effective in one-third of patients.

Furthermore, the median survival rate is 12 to 15 months from diagnosis, meaning there is a demand in the market for superior treatments.

GDC-0084 value proposition

The GDC-0084 value proposition is considerable:

• Currently in Phase II clinical trials, under IND with US FDA, at leading US centese for brain cancer;
• Clear Phase I data, with favourable safety profile and indications of efficacy in late-stage GBM patients;
• Clear unmet medial need, with only existing therapy working in about 35% of patients;
• Defined >US$1 billion market potential for GBM alone;
• PI3K is a well-validated onco-target, with three existing therapies on market, but GDC0084 uniquely differentiated by ability to cross blood-brain barrier;
• Key inflection point due in 2H 2019, and additional indication investigator studies ongoing with updates in 2019; and
• High potential for accelerated approval by FDA.

Cantrixil in clinical trial

As well as GDC-0084, Kazia is developing Cantrixil to treat ovarian cancer which is currently in a phase I clinical trial in Australia and the United States.

Cantrixil is a third-generation benzopyran molecule with activity against cancer stem cells.

Kazia expects a read-out of maximum tolerated dose and safety from its phase I study in ovarian cancer in the current June half.

The Sydney-based oncology-focused biotechnology company is well-funded to see both programs through key data read-outs.

Register for the CEO Sessions today to find out more.

Sydney details, Monday, February 18, 2019

Melbourne details, Tuesday, February 19, 2019

Also featuring at both sessions will be AdAlta Ltd (ASX:1AD), Argonaut Resources NL (ASX:ARE) and Peninsula Energy Ltd (ASX:PEN) while Theta Gold Mines Ltd (ASX:TGM) is on the Sydney program and Anatara Lifesciences Ltd (ASX:ANR) is on the Melbourne program.

 

]]>
Thu, 07 Feb 2019 11:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214129/kazia-therapeutics-will-outline-anti-cancer-drug-development-strategy-at-ceo-sessions-214129.html
<![CDATA[News - Kazia Therapeutics progresses phase II clinical trial for brain cancer drug ]]> https://www.proactiveinvestors.com.au/companies/news/193977/kazia-therapeutics-progresses-phase-ii-clinical-trial-for-brain-cancer-drug-193977.html Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has commenced an international phase II clinical trial of its lead program, GDC-0084, a developing brain cancer drug.

GDC-0084 is being developed for glioblastoma multiforme, the most common and most aggressive form of primary brain cancer.

Chemotherapy treatment temozolomide is only effective in one-third of patients.

Furthermore, the median survival rate is 12 to 15 months from diagnosis, meaning there is a demand in the market for superior treatments.

Kazia’s CEO Dr James Garner said: “The need for new therapies in this disease remains immense, and we believe that GDC-0084 may have a valuable role to play in improving outcomes for patients with glioblastoma.”

FDA grant in February paved way for phase II clinical trial

Commencement of the trial follows the decision of the US FDA to grant orphan drug designation to GDC-0084 in glioblastoma in February 2018.

This phase II study will initially be conducted predominantly at leading US-based centres.

The study will commence screening patients after the Easter holidays.

It is anticipated that the study will provide an initial data read-out in early calendar 2019.

Phase II builds on a successful phase I study

Kazia licensed GDC-0084 in late 2016 from Genentech, a member of the Roche Group, where it had previously completed a phase I clinical study in 47 patients with advanced glioma.

Genentech’s phase I study demonstrated a favourable safety profile and provided signals of efficacy.

Genentech also conducted an extensive preclinical program which showed encouraging results for GDC-0084 in animal models of glioblastoma.

Two clinical-stage programs

Kazia is an emerging cancer-focused biotech with two clinical-stage programs.

As well as GDC-0084, Kazia is developing Cantrixil to treat ovarian cancer which is currently in phase I trial.

Kazia expects a read-out of maximum tolerated dose and safety from its phase I study in ovarian cancer in the current June half.

]]>
Thu, 29 Mar 2018 08:28:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193977/kazia-therapeutics-progresses-phase-ii-clinical-trial-for-brain-cancer-drug-193977.html